Baseret på lægemidlets metabolisme er det usandsynligt, at agalsidase beta vil medføre cytochrom P450 - relateret lægemiddelinteraktion.
Based on its metabolism, agalsidase beta is an unlikely candidate for cytochrome P450 mediated drug-drug interactions.